EBITDA for Vertex Pharmaceuticals (VRTX)
According to Vertex Pharmaceuticals's latest reported financial statements, the company's current EBITDA (TTM) is $4.83B USD. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingEBITDASwitch metric
TTM (last 4 quarters)
$4.83B
YoY change
+921.6%
5Y CAGR
+8.6%
Peak year (2025)
$4.97B
Cumulative EBITDA
$18.52B
EBITDA history chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025
EBITDA history table for Vertex Pharmaceuticals (VRTX) from 1990 to 2025
| Fiscal year | Period ended | Reported | EBITDA | YoY |
|---|---|---|---|---|
| 2025 | $4.97B | +921.6% | ||
| 2024 | $486.30M | -89.4% | ||
| 2023 | $4.61B | +3.8% | ||
| 2022 | $4.44B | +52.0% | ||
| 2021 | $2.92B | -11.2% | ||
| 2020 | $3.28B | +110.5% | ||
| 2019 | $1.56B | +120.8% | ||
| 2018 | $706.78M | +584.5% | ||
| 2017 | $103.26M | +36.8% | ||
| 2016 | $75.46M | -118.3% | ||
| 2015 | -$411.25M | -31.3% | ||
| 2014 | -$598.75M | +7.9% | ||
| 2013 | -$554.75M | -1406.4% | ||
| 2012 | $42.46M | -68.3% | ||
| 2011 | $133.94M | -119.0% | ||
| 2010 | -$704.89M | +17.7% | ||
| 2009 | -$598.88M | +40.5% | ||
| 2008 | -$426.19M | +10.6% | ||
| 2007 | -$385.21M | +93.1% | ||
| 2006 | -$199.52M | +74.3% | ||
| 2005 | -$114.45M | +6.4% | ||
| 2004 | -$107.59M | -59.3% | ||
| 2003 | -$264.53M | +115.0% | ||
| 2002 | -$123.05M | +26.7% | ||
| 2001 | -$97.14M | +294.0% | ||
| 2000 | -$24.65M | -44.4% | ||
| 1999 | -$44.30M | +2.5% | ||
| 1998 | -$43.20M | +176.9% | ||
| 1997 | -$15.60M | -57.0% | ||
| 1996 | -$36.30M | +59.2% | ||
| 1995 | -$22.80M | +32.6% | ||
| 1994 | -$17.20M | -437.3% | ||
| 1993 | $5.10M | -170.8% | ||
| 1992 | -$7.20M | +89.5% | ||
| 1991 | -$3.80M | -7.3% | ||
| 1990 | -$4.10M | — |
EBITDA values are taken from Vertex Pharmaceuticals's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
As of the 2025 fiscal year, Vertex Pharmaceuticals (VRTX) reported EBITDA of $4.97B – surged 921.6% year-over-year.
Across 2020–2025 (5 years), Vertex Pharmaceuticals EBITDA produced a CAGR of +8.6% – with the latest reading among the more recent periods of the dataset.
The highest annual EBITDA of $4.97B was reported in 2025. The lowest in the available history was -$704.89M in 2010.
Vertex Pharmaceuticals (VRTX) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $24.21B.
Vertex Pharmaceuticals EBITDA by Year
Vertex Pharmaceuticals EBITDA 2025: $4.97B
Vertex Pharmaceuticals EBITDA in 2025 was $4.97B, surged 921.6% from 2024. This figure represents the highest annual value in the available history.
Vertex Pharmaceuticals EBITDA 2024: $486.30M
Vertex Pharmaceuticals EBITDA in 2024 was $486.30M, plunged 89.4% below 2023.
Vertex Pharmaceuticals EBITDA 2023: $4.61B
Vertex Pharmaceuticals EBITDA in 2023 was $4.61B, edged up 3.8% from 2022.
Vertex Pharmaceuticals EBITDA 2022: $4.44B
Vertex Pharmaceuticals EBITDA in 2022 was $4.44B, surged 52.0% from 2021.
Vertex Pharmaceuticals EBITDA 2021: $2.92B
Vertex Pharmaceuticals EBITDA in 2021 was $2.92B.
See more financial history for Vertex Pharmaceuticals (VRTX).
Sector peers — EBITDA
Companies in the same sector as Vertex Pharmaceuticals, ranked by their latest EBITDA.
| Company | EBITDA | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $156.73B | Healthcare |
| Johnson & Johnson (JNJ) | $41.05B | Healthcare |
| Eli Lilly and Company (LLY) | $27.94B | Healthcare |
| Merck & Co., Inc. (MRK) | $25.36B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $23.06B | Healthcare |
| AstraZeneca PLC (AZN) | $19.83B | Healthcare |
| AbbVie Inc. (ABBV) | $17.63B | Healthcare |
| Amgen Inc. (AMGN) | $15.84B | Healthcare |
Frequently asked questions
What is Vertex Pharmaceuticals's EBITDA?
- Latest reported EBITDA for Vertex Pharmaceuticals (VRTX) is $4.83B (period ending December 31, 2025).
How has Vertex Pharmaceuticals EBITDA changed year-over-year?
- Vertex Pharmaceuticals (VRTX) EBITDA changed +921.6% year-over-year on the latest annual filing.
What is the long-term growth rate of Vertex Pharmaceuticals EBITDA?
- Vertex Pharmaceuticals (VRTX) EBITDA compound annual growth rate is +8.6% over the most recent 5 years available.
When did Vertex Pharmaceuticals EBITDA hit its highest annual value?
- Vertex Pharmaceuticals EBITDA reached its highest annual value of $4.97B in 2025.
What was Vertex Pharmaceuticals EBITDA in 2024?
- Vertex Pharmaceuticals (VRTX) EBITDA in 2024 was $486.30M.
What was Vertex Pharmaceuticals EBITDA in 2025?
- Vertex Pharmaceuticals (VRTX) EBITDA in 2025 was $4.97B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
VRTX Overview
Company profile, financial tools, and key metrics
VRTX Revenue Counter
Earns $381.74 every second. See per minute, hour, and day.
VRTX Earnings Counter
Earns $125.36 per second net profit. See per minute, hour, and day.
VRTX Economic Scale
Exceeds Somalia, Fed. Rep.'s GDP. Compare with world economies.
VRTX What If Invested
What if you had invested $1,000? See historical returns from any date.
VRTX How It Makes Money
Discover visual breakdown of $12.04B in revenue — where it comes from and where it goes.
VRTX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
VRTX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
VRTX Daily Price Character
Explosive · 48.3% historical win rate (green days). Streaks & record days.
VRTX Buybacks
1.75% TTM buyback yield. Shareholder yield & SBC comparison.
VRTX Stock Split History
1 split on record. Dates, ratios, and cumulative multiple.